Form 4: Zevra Therapeutics Executive Joshua Schafer Sells Shares Under 10b5-1 Plan

Joshua Schafer, CCO & EVP of Business Development at Zevra Therapeutics, sold 10,500 shares of common stock at a price of $7.8597 per share on February 13, 2025, according to a Form 4 filing with the SEC.

Summary

• On February 13, 2025, Joshua Schafer, the CCO & EVP of Business Development at Zevra Therapeutics, sold 10,500 shares of common stock.
• The sale was executed at a price of $7.8597 per share.
• This transaction was made pursuant to a pre-arranged 10b5-1(c) plan adopted on October 15, 2024.
• Following the transaction, Schafer directly owns 29,486 shares of Zevra Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to an insider stock sale under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information about the transaction.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders buy or sell their company's stock. They provide transparency into insider transactions and can be used by investors to gauge management's sentiment about the company's prospects.

Stakeholder Impact

• Shareholders may interpret the insider sale as a neutral event, given it was conducted under a pre-arranged 10b5-1 plan.

Key Dates